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Background: In critically ill patients with pneumonia, accurate microorganism identification allows appropriate
antibiotic treatment. In patients undergoing bronchoalveolar lavage (BAL), direct examination of the fluid using
Gram staining provides prompt information but pathogen identification accuracy is low. Culture of BAL fluid is
actually the reference, but it is not available before 24 to 48 h. In addition, pathogen identification rate observed
with direct examination and culture is decreased when antibiotic therapy has been given prior to sampling. We
therefore assessed, in critically ill patients with suspected pneumonia, the performance of a multiplex PCR (MPCR)
to identify pathogens in BAL fluid. This study is a prospective pilot observation.
Methods: We used a MPCR detecting 20 types of microorganisms. Direct examination, culture, and MPCR were
performed on BAL fluid of critically ill patients with pneumonia suspicion. The final diagnosis of infective
pneumonia was retained after the medical chart was reviewed by two experts. Pathogen identification rate of
direct examination, culture, and MPCR in patients with confirmed pneumonia was compared.
Results: Among the 65 patients with pneumonia suspicion, the diagnosis of pneumonia was finally retained in 53
cases. Twenty nine (55%) were community-acquired pneumonia and 24 (45%) were hospital acquired. Pathogen
identification rate with MPCR (66%) was greater than with culture (40%) and direct examination (23%) (p =0.01 and
p <0.001, respectively). When considering only the microorganisms included in the MPCR panel, the pathogen
identification rate provided by MPCR reached 82% and was still higher than with culture (35%, p <0.001) and direct
examination (21%, p <0.001). Pathogen identification rate provided by MPCR was not modified in the case of
previous antibiotic treatment (66% vs. 64%, NS) and was still better than with culture (23%, p <0.001).
Conclusions: The results of this pilot study suggest that in critically ill patients, MPCR performed on BAL fluid could
provide higher identification rate of pathogens involved in pneumonia than direct examination and culture,
especially in patients having received antimicrobial treatment.
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In critically ill patients with pneumonia, antibiotic therapy is
mandatory to improve prognosis and should be adminis-
tered as soon as possible, In the case of ventilator-associated
pneumonia, inappropriate antibiotic therapy might increase
the length of stay in intensive care units (ICU) and even
double mortality [1-3].
The spectrum of antibiotic therapy should be adapted
as soon as microbial identification is available. Gram
staining of respiratory samples obtained with protected
distal sampling, or bronchoalveolar lavage (BAL) is rapid
but its sensitivity is low [4,5]. The results of quantitative
culture of these specimens are available only 24 to 48 h
later. Furthermore, the sensitivity of culture is decreased
by prior antimicrobial therapy, especially if antibiotics
have been introduced recently [6,7].
Recent rapid PCR-based techniques provide information
allowing prompt pathogen identification even after initi-
ation of antibiotic therapy. The LightCycler SeptiFast®
(Roche Diagnostics, Mannheim, Germany) is a real-time
multiplex PCR (MPCR) assay which can identify 20 bac-
terial and fungal species accounting for up to 95% of cases
of bacteraemia (Table 1), from a single whole blood sam-
ple. This analysis requires between 5 and 6 h with manual
DNA extraction and 4 h with automated extraction [8].
Initially, the LightCycler SeptiFast® was designed to identify
rapidly the most important microorganisms responsible for
bacteraemia in patients with hematological malignancies
[9,10] or cancer [11], especially during febrile neutropenia
[12]. This technique was evaluated using blood samples of
patients admitted to the ICU [13], emergency units [14], or
ward [15,16]. These studies have shown that MPCR can be
simultaneously used with blood culture-based methods in
order to improve pathogen identification rate in patients
who had received antimicrobials. A study focusing on pa-

















Streptococcus spp. Enterobacter (cloacae/
aerogenes)
Candida krusei
Enterococcus faecium Proteus mirabilis Candida glabrata
Enterococcus faecalis Pseudomonas aeruginosa Aspergillus (fumigatus)
Acinetobacter baumannii
Stenotrophomonas
maltophiliavalve culture, MPCR performed on the valve tissue signifi-
cantly increased pathogen identification [17].
The aim of the present study was to determine in ICU
patients with pneumonia whether MPCR usually per-
formed on the blood culture could be performed on BAL
fluid and could improve pathogen identification rate com-
pared to usual microbiological analysis of BAL fluid.
Methods
Setting and patients
We conducted this pilot study in our 15-bed medical ICU.
On average thousand patients per year are admitted from
the units of the hospital (mainly hepatology with liver
transplantation, hematology, oncology, infectious diseases,
gastroenterology), emergency unit and mobile emergency
unit. For availability issue, we had the kits only during two
nonconsecutive periods, from April to September 2009
and from February to July 2010.
This study was approved by the Ethics Committee of
the Société de Réanimation de Langue Française (SRLF).
All consecutive patients admitted to the ICU with sus-
pected community-acquired pneumonia (CAP) or hospital-
acquired pneumonia (HAP) (including ventilator-acquired
pneumonia (VAP)) were eligible. An informed consent was
given by the patient or by a legal representative if the pa-
tient was unable to consent.
Diagnosis of suspected CAP was based on the Inter-
national Sepsis Forum Definition of Infection in the ICU
[18], using clinical, radiological, and biochemical criteria:
cough, dyspnea, chest pain, sputum, fever, tachycardia,
tachypnea, confusion, localized dullness, body temperature
more than 38.3°C, the presence of persistent crackles dur-
ing deep inspiration, the presence of pulmonary infiltrate
on the hospital admission chest X-ray or appearing within
48 h of hospital stay, and leukocytosis (>10,000/mL) or
leukopenia (<4,000/mm3).
Suspicion of hospital-acquired pneumonia was based
on American Thoracic Society guidelines [19,20] and
was defined as: more than 48 h after hospital admission,
new or persistent infiltrate on chest X-ray associated
with at least two of the following: purulent tracheal secre-
tions, temperature >38°C, and leukocyte count >11,000
or <4,000/mm3.
In the case of clinical and bacteriological suspicion of
pneumonia with inconclusive chest X-ray, a chest CT
scan was performed to confirm the diagnosis.
Data collection
For every eligible patient, the following data were system-
atically recorded: age, gender, simplified acute physiology
score II (SAPS II), type of pneumonia (CAP or HAP (in-
cluding VAP)), underlying immunodeficiency [defined as
one of the following: AIDS, cancer or hematological dis-
ease with chemotherapy administered less than 30 days
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marrow transplant, corticosteroids more than 1 mg/kg/
day equivalent prednisone for more than 1 month, and
other immunosuppressive therapies], core temperature,
septic shock according to international definitions [21], in-
vasive mechanical ventilation, type of pulmonary infiltrate
(multilobular or not, alveolar, interstitial or mixed),
leukocyte counts, plasma C-reactive protein and procalci-
tonin levels, cytology of the BAL, administration of a re-
cent antibiotic treatment (defined as a new antibiotic
therapy initiated within 48 h before BAL), and results of
all microbiological specimens obtained during 2 days be-
fore or after BAL and in ICU mortality.
Procedures and analysis
In our unit, fiberoptic bronchoscopy is performed by a
senior intensivist and is therefore available 24 h a day,
7 days a week. Every spontaneously breathing patient
with suspected pneumonia underwent fiberoptic bron-
choscopy via the nasal route after local anesthesia with
topical lidocaine. When the patient was receiving inva-
sive mechanical ventilation, the fiberoptic bronchoscopy
was performed through the endotracheal tube under
general anesthesia. Bronchoalveolar lavage was per-
formed in the bronchial segment corresponding to the
pulmonary infiltrate present on the chest X-ray. In the
case of diffuse pulmonary abnormalities, the bronchial
segment where the infiltrate was the most important or
the middle right bronchus was sampled.
Briefly, five aliquots of 20 mL of 0.9% saline were pre-
pared. The first was discarded as recommended [22]. The
others were pooled and separated into three aliquots. The
first aliquot was sent to the microbiology lab for direct
examination (DE) with Gram coloration and culture (C).
The positivity threshold of C after 24 h was 104/mL.
The second aliquot was frozen and kept stored at −20°C
for MPCR, and the last one was sent for cytological ana-
lysis. Considering that the results provided by MPCR were
not taken into account to treat the patient and that the
DNA structure remains long-term stable in frozen bio-
logical samples [23], MPCR was not performed in real time
but LBA samples dedicated to PCR were analyzed six by six
using the automated platform.
The dedicated MPCR frozen stored aliquots were
thawed, and the tests were performed using 1.5 mL of
BAL fluid. The guidelines provided by the manufacturer
for blood samples were followed, except that the sample
lysis step (of red and white blood cells) was not performed.
A positive and a negative control were included in each
experiment. Briefly, DNA was extracted using a MPCR
Prep Kit (Roche Diagnostics, Mannheim, Germany). Real-
time PCR amplification was performed using an MPCR
Kit with the LightCycler 2.0 instrument. Internal controls
were included in the assay.As for culture, detection by MPCR of one of the fol-
lowing: Coagulase-negative Staphylococci (CNS), Strepto-
coccus spp., Enterococcus faecalis, Enterococcus faecium,
and Candida spp. was not taken into account unless
they were the sole or largely predominant pathogen in
immunocompromised patients.
One week after ICU admission, according to the clinical
evolution, chest radiograph, and results of DE, C, and
other conventional microbiological samples, all medical
files were assessed in a blinded manner by two senior phy-
sicians to rule in or not the diagnosis of infectious pneu-
monia. In the case of discrepant conclusions, the data
were assessed by a third senior intensivist until a consen-
sus was obtained. Physicians analyzing the data as well as
physicians in charge of the patients were blinded to the re-
sults of the MPCR.
Based on the clinical history, clinical examination,
radiological file, biological results, and of other contem-
porary microbiological samples (blood cultures, tracheal
aspiration, Streptococcus pneumoniae, and Legionella
pneumoniae antigenuria), the diagnosis of infectious
pneumonia was ruled in or ruled out and the MPCR re-
sults were assessed and compared with the results of DE
and C.
Statistical analysis
Variables are expressed as mean ±1 SD. Proportions
were compared using the Fisher exact test for independ-
ent samples and the McNemar chi-square test for
matched pairs. All statistical tests were two sided at a
5% level of significance. All statistical computations were
performed using SAS software version 9.2 (SAS Institute
Inc, Cary, NC, USA).
Results
During the study periods, pneumonia was suspected in 65
patients and finally confirmed in 53 of them (age: 61 ±
16 years, SAPS II: 48 ± 25, invasive mechanical ventilation
requirement: 57%, septic shock: 32%, immunosuppression:
45%). The chest X-ray showed the pneumonia in 47 pa-
tients. In six patients, the pneumonia was visible only in
the chest CT scan. The types of pneumonia broke as fol-
lows: CAP (n = 29) and HAP (n = 24). Among the HAP,
nine were VAP (in 2009, it was declared 27 VAP with
16.6% of incidence density and in 2010, 34 VAP with
17.43% of incidence density).
Demographics and clinical characteristics of the 65 pa-
tients with suspected pneumonia are summarized in
Table 2.
Among the 12 patients for whom pneumonia was fi-
nally ruled out, alternative diagnosis was: intra-alveolar
hemorrhage (n = 3), hemodynamic pulmonary edema
(n = 2), a vacuo edema complicating pneumothorax
exsufflation (n = 1), pulmonary fibrosis (n = 1), and acute






(n = 12)CAP = 29
HAP = 24
(with 9 VAP)
Gender (male to female ratio) 62.7% 25%
Mean age (years) 61.1 ± 16.4 55 ± 15.3
SAPS II 48.4 ± 25,1 38.8 ± 17
Immunodeficiency 24 (45.3%) 6 (50%)
HIV 8 0
Neoplasia/hematologic disease 6/4 0/2
Systemic disease 4 3
Inflammatory bowel disease 1 1
Liver transplant 1 0
Immunosuppressive therapy 14 (26.4%) 8 (66.6%)
Antineoplastic chemotherapy 7 1
Corticosteroids 5 6
Anti-TNF antibodies 0 2
Azathioprine 1 0
Previous antibiotic therapy 74% 83%
Clinical characteristics
Temperature <36° or >38° 28 (52.8%) 4 (33.3%)
Confusion 7 (13.2%) 3 (25%)
Shock 18 (33.9%) 4 (33.3%)
Mechanical ventilation 29 (54.7%) 8 (66.6%)
Radiologic findings
Multilobar infiltrates 27 (50.9%) 11 (91.6%)
Laboratory findings
Leucocytes >11,000/mm3 31 (58.4%) 11 (91.6%)
Leucocytes <3,000/mm3 8 (15%) 2 (15.6%)
CRP 204 ± 139 125 ± 100







Polynuclear cells (%) 78.19 ± 11.03 76.81 ± 16.55
CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia;
VAP, ventilator-acquired pneumonia.
Table 3 Comparison of diagnosis provided by direct
examination, culture, and MPCR
Direct examination Culture MPCR
+ + + n = 9
+ + − n = 1
+ − + n = 0
+ − − n = 1
− + + n = 6
− + − n = 5
− − + n = 20







53 patients with a final diagnosis of pneumonia. $p <0.001 for DE vs. MPCR;
£p =0.01 for C vs. MPCR.
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lated to extrapulmonary sepsis (n = 5). Of these five pa-
tients, one had an infection of ascites with septic shock
(PCT <0.5 ng/mL), one had a pyelonephritis with septic
shock (PCT >10 ng/mL), one had a peritonitis with sep-
tic shock (PCT not available), one had a liver abscess
without shock (PCT >10 ng/mL), and one had a pyelo-
nephritis without shock (PCT >10 ng/mL).At the time of the BAL, 39 patients (74%) were receiving
recent antibiotic therapy (patients with CAP: 18 (62%), pa-
tients with HAP: 21 (87%)). The reasons for this antibiotic
treatment were: pneumonia (n = 27), bronchitis (n = 4),
bactaeremia associated with febrile neutropenia (n = 2), fe-
brile neutropenia without bactaeremia (n = 2), urinary
tract infection (n = 2), arthritis-associated bactaeremia
(n = 1), and intra-abdominal infection (n = 1).
The results of pathogen identification provided by DE, C,
and MPCR are depicted in Tables 3 and 4. Pathogen identi-
fication rate provided by MPCR (66%) was significantly
higher than the ones provided by DE (23%, p <0.001) and C
(40%, p = 0.01), irrespective of whether pneumonia was
community or hospital acquired.
When DE was negative, MPCR was markedly more
often positive than C (63% vs. 27%, p = 0.0007). Using
data provided by other microbiological tests (Pneumo-
cystis jirovecii PCR, H1N1 PCR, tracheal aspirate during
the 48 h preceding BAL, urinary pneumococcal antigen),
a pathogen identification was obtained in five supple-
mental cases, resulting in a final pathogen identification
in 48/53 cases (90%). All the five patients, for whom all
microbiological examinations were negative, were receiv-
ing recent antibiotic therapy when BAL was performed.
Considering the 20 cases (38%) of pneumonia for
which pathogen identification was provided by MPCR
but neither by DE nor by C, 25 bacterial species were
identified (Table 3): S. pneumoniae (n = 4), Escherichia
coli (n = 6), Staphylococcus aureus (n = 5), Pseudomonas
aeruginosa (n = 4), Serratia (n = 2), Klebsiella (n = 2), and
Enterobacter cloacae (n = 2). In these 20 patients, MPCR
results were confirmed by other microbiological investiga-
tions for 11 of them [blood culture (n = 4), previous tra-
cheal aspirate during the 48 h preceding BAL (n = 5),
urinary pneumococcal antigen (n = 2)]. Nine of these 11
patients were receiving recent antibiotic therapy when









1 Yes 0 0 E. coli/P. aeruginosa TA E. coli/P. aeruginosa Yes
1 day before BAL
2 Yes 0 0 S. aureus No Yes
3 No GPD S. pneumoniae 104/mL S. pneumoniae No Yes
4 No GPD S. pneumoniae 105/mL S. pneumoniae No Yes
5 Yes 0 0 P. aeruginosa Blood culture P. aeruginosa Yes
1 day before BAL
6 Yes 0 0 E. cloacae No Yes
7 Yes 0 0 0 AgU S. pneumoniae Yes
On BAL day
8 Yes GNB E. coli 103/mL E. coli Blood culture E. coli Yes
On BAL day
9 Yes 0 0 0 No No
10 Yes 0 S. aureus 104/mL/
P. aeruginosa 103/mL
S. aureus/P. aeruginosa No Yes
11 No 0 0 E. coli/Klebsiella spp./S. aureus TA S. aureus/Klebsiella spp. Yes
On BAL day
12 Yes 0 0 E. cloacae/S. aureus TA E. cloacae Yes
On BAL day
13 No GNB E. coli 105/mL E. coli No Yes
14 Yes 0 0 0 No No
15 No 0 S. pneumoniae 106/mL S. pneumoniae No Yes
16 Yes 0 0 S. marcescens/E. coli TA S. marcescens/E. coli Yes
1 day before BAL
17 Yes P. jirovecii 0 0 No Yes
18 No 0 Haemophilus 105/mL 0 No Yes
19 No 0 S. pneumoniae 105/mL S. pneumoniae No Yes
20 Yes GNB E. cloacae 103/mL E. cloacae No Yes
21 Yes 0 0 S. pneumoniae AgU S. pneumoniae Yes
On BAL day
22 Yes 0 0 0 No No
23 No GPD S. pneumoniae 104/mL S. pneumoniae Blood culture S. pneumoniae Yes
On BAL day
24 Yes GPD S. pneumoniae 103/mL S. pneumoniae AgU S. pneumoniae Yes
1 day after BAL
25 Yes 0 0 0 No No
26 No 0 Haemophilus 103/mL 0 No Yes
27 Yes 0 0 P. aeruginosa Blood culture P. aeruginosa Yes
On BAL day
28 Yes 0 0 E. coli No Yes
29 Yes 0 S. pneumoniae 102/mL S. pneumoniae AgU S. pneumoniae Yes
The same day
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Table 4 Pathogens identified by direct examination, culture, and/or MPCR according to previous administration of
antibiotic therapy (Continued)
30 Yes 0 0 E. coli Blood culture E. coli Yes
1 day before BAL
31 No 0 Haemophilus 105/mL 0 No Yes
32 Yes 0 0 S. aureus No Yes
33 Yes 0 0 S. pneumoniae No Yes
34 Yes 0 0 0 PCR P. jirovecii Yes
4 days after
35 Yes 0 0 K. pneumoniae No Yes
36 No 0 S. aureus 105/mL S. aureus No Yes
37 Yes 0 0 S. pneumoniae No Yes
38 Yes 0 H. alvei 104/mL 0 No Yes
39 Yes 0 0 0 PCR H1N1 Yes
2 days after
40 Yes 0 0 S. aureus No Yes
41 Yes 0 0 P. aeruginosa No Yes
42 Yes 0 K. pneumoniae 104/mL K. pneumoniae No Yes
43 No 0 0 S. pneumoniae AgU S. pneumoniae Yes
The same day
44 Yes 0 0 0 No No
45 Yes 0 L. pneumophila 0 No Yes
46 Yes P. jirovecii 0 0 No Yes
47 Yes GPC S. epidermidis 105/mL S. epidermidis Blood culture S. epidermidis Yes
1 day before BAL
48 No GNB E. coli 106/mL E. coli No Yes
49 No GNB Haemophilus 105/mL 0 No Yes
50 Yes 0 0 S. marcescens TA S. marcescens Yes
On BAL day
51 Yes 0 0 0 TA Haemophilus Yes
1 day before BAL
52 Yes 0 0 0 TA S. pneumoniae Yes
On BAL day
53 Yes 0 0 E. coli Blood culture E. coli Yes
1 day after
GPD, gram-positive diplococci; GNB, gram-negative bacilli; GPC, gram-positive cocci; TA, tracheal aspirate; AgU S. pneumoniae, urinary antigen test for S. pneumoniae.
The date following the samples corresponds to the day when the sample was performed. Bold lines represent the pathogens not included in the detection panel of the
MPCR assay.
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whom MPCR was the only positive microbiological test,
were all receiving recent antibiotic therapy when BAL was
performed.
Among the 48 patients with a microbiological identifica-
tion provided by at least one method, MPCR did not pro-
vide any pathogen identification in 13 of them. All the
pathogens retained as causing these 13 pneumonia werenot included in the panel of strains detected by MPCR ex-
cept S. pneumoniae (in two patients). Pathogens not iden-
tified by MPCR were identified by 1) direct examination
or culture: P. jirovecii (n = 2), Legionella pneumophila
(n = 1), Haemophilus influenzae (n = 4), and Hafnia alvei
(n = 1); 2) tracheal aspirate obtained 24 h earlier (S. pneu-
moniae(n = 1), H. influenzae (n = 1); 3) specific PCR
H1N1 virus (n = 1), PCR P. jirovecii (n = 1); or 4) urinary
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lysis to the microorganisms theoretically detected by
MPCR, pathogen identification rate provided increased to
82%, while it was 35% (p <0.001) and 21% (p <0.001) for
culture and direct examination, respectively.
In patients for whom pneumonia diagnosis was finally
ruled out, MPCR detected a pathogen in 5/12 patients
(42%). This was considered as colonization.
When patients had received recent antibiotic therapy
prior to BAL, pathogen identification rate with MPCR was
not modified (64%) and remained higher than with direct
examination (15%, p <0.001) or culture (23%, p <0.001)
(Figure 1).
Discussion
The present study is the first to assess whether MPCR
performed on BAL fluid enables pathogen identification
complementary with the direct examination and the cul-
ture in patients with severe pneumonia. Recently pub-
lished guidelines recommend antibiotic administration
within 1 h for patients suspected of having septic shock
or severe sepsis [24]. During severe infection, empirical
antibiotic therapy is inappropriate in roughly one-third
of cases, and this substantially increases mortality and
hospital length of stay [25]. In the setting of infection,
any tool enabling prompt and accurate documentation
of pathogen might theoretically reduce mortality and
may serve to improve hospital resource use [25].
During two nonconsecutive periods, in unselected critically
ill patients with community or hospital-acquired pneumonia,
we performed, as usually done in our unit, bronchoalveolar
lavage during fibroscopic examination. Results of direct








Direct examination Culture Multi
Figure 1 Identification rate (percentage) of pathogen provided by dir
patients having received previous administration of antibiotics.provided as soon as possible and guided antibiotic therapy.
A MPCR processed on BAL fluid was performed after a
delay of several days, and its results were not taken into ac-
count to modify antibiotic therapy management.
Final diagnosis of pneumonia relied on a posteriori
analysis of clinical, radiological, and microbiological
data. This analysis was conducted by two senior physi-
cians who were blinded to MPCR results.
The present data also suggest that MPCR can be done
on samples having been kept frozen for several days. This
study increases the number of biological fluid on which
MPCR can be of interest. Reliable results obtained more
quickly with MPCR (performed on urine samples) than
with culture have been observed during urinary tract in-
fection, [26]. Similar date was observed on other fluids
(biliary, pleural, peritoneal, or intra-articular fluid) [27,28].
Multiplex PCR significantly increased the identifica-
tion rate of pathogen causing pneumonia, compared
with usual culture alone. Increased pathogen identifica-
tion rate provided by MPCR compared to conventional
cultures has been reported during the course of blood-
stream infections [9,16,29,30], febrile neutropenia [12],
and persistent fever [31].
In the present study, pathogen identification rate would
have probably be higher if the panel of the MPCR had in-
cluded microorganisms frequently causing pneumonia like
H. influenzae, L. pneumophila, H. alvei, respiratory viruses,
and P. jirovecii. These pathogens were considered as the
cause of pneumonia in 8/18 of the cases for which MPCR
did not provide microbiological identification, while direct
examination and/or culture did.
The contribution of MPCR to pathogen identification




ect examination, culture, and multiplex PCR. In all patients and in
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provided by MPCR was not modified (compared to
identification rate observed in all patients) while it de-
creased for direct examination and culture. This issue is
in keeping with which was observed in other types of
infection [32-34].
Owing to its ability to provide pathogen identification
more frequently than direct examination and culture
MPCR could allow earlier initiation of appropriate anti-
biotic therapy [29].
In our study, if the MPCR has been done in real time, the
initial antibiotic therapy, appropriate in 87% (46/53), would
have been changed in nine patients: deescalation in seven
cases (anti staphylococcus antibiotic therapy (n = 2), anti
P. aeruginosa antibiotic therapy (n = 1), anti S. pneumoniae
antibiotic therapy (n = 4), change of antibiotic therapy in
two cases (anti staphylococcus antibiotic)).
Direct examination provides information in less than
2 h, but the diagnostic input of direct examination per-
formed on BAL fluid was weak in our study, and it iden-
tified pathogens in only 23% of patients.
Our study has nevertheless several limitations. First, this
was a monocenter study performed on a limited number of
nonconsecutive patients. These promising data need to be
confirmed on more large ICU population, especially in the
subgroup of patients (immunosuppressed patients). Second,
due to logistical and economical consideration, MPCR ana-
lysis was pooled and was not performed in real time. A trial
assessing the impact of MPCR performed in real time in
critically ill patients with pneumonia warrants consider-
ation. Third, the time required by the technique (4 to 6 h)
to provide microbiological results could be considered
excessive, since currently available fully automated PCR
platforms provide results in 1 h. It should be highlighted
that these latter PCR kits use a single probe and can only
identify a single microorganism (S. aureus, Mycobacterium
tuberculosis, or Clostridium difficile [35-38]). On the other
hand, mass spectrometry yields results in a very short time
(few minutes), but it requires that the microorganism has
been isolated [39,40].
Multiplex PCR has nevertheless some limits. First,
MPCR performed on BAL fluid cannot give quantitative
results and is therefore unable to differentiate colonization
from infection.
In considering the number of cycles required for
obtaining positivity, it could be possible to approach the
distinction between colonization and infection (similarly
to what is done for P. jirovecii). However, in patients
having received antibiotic therapy prior to BAL but hav-
ing suggestive anamnesis, clinical examination, evolution
radiological and biological results, and of other contem-
porary microbiological results, should the diagnosis of
pneumonia be ruled out when culture provided less col-
ony forming unit than the threshold?Culture remains the gold standard of routine investiga-
tion to obtain quantitative data and confirm infection, es-
pecially in the case of ventilator-acquired pneumonia [41].
However, in association with C, MPCR appears highly
relevant to identify organisms likely involved in pneumo-
nia, allowing thus administration of the most appropri-
ate antibiotic therapy.
On other hand, unlike the culture, MPCR does not
provide antibiotic susceptibility testing and culture re-
mains fundamental.
Cost must also be taken into consideration, since
MPCR is three times more expensive than C, and the
cost-effectiveness of a diagnostic strategy using MPCR
has to be assessed. It may be appropriate to limit MPCR
to the most severely ill patients in the ICU [42]. On the
other hand, MPCR which could decrease the use of
antibiotics [43] might decrease the rate of inappropriate
antibiotic therapy and therefore decrease the anti-
microbial resistance development [25].
Conclusions
In conclusion, our study conducted in patients with se-
vere pneumonia is the first to assess whether MPCR per-
formed on BAL fluid enables pathogen identification.
Our data suggest that MPCR provides higher identifica-
tion rate than conventional microbiological methods.
MPCR could be particularly valuable in patients with re-
cent antibiotic treatment.
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